Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90042/1/j.1365-2516.2011.02612.x.pd
Introduction: This study compared the efficacy of Aryoseven with Novoseven to control bleeding episo...
Haemophilia therapy has undergone very rapid evolution in the last 10 years. The major limitation of...
Aims: Prophylaxis with standard-acting recombinant factor IX (rFIX) in hemophilia B patients require...
Heng Joo Ng, Lai Heng LeeDepartment of Haematology, Singapore General Hospital, SingaporeAbstract: I...
Self‐administration of factor and bypassing agents by persons with hemophilia in the home setting is...
On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and m...
The Hemostasis and Thrombosis Research Society Registry was used to monitor the postapproval use and...
The availability of recombinant activated factor VII (rFVIIa, eptacog alfa activated) has greatly ad...
The availability of recombinant activated factor VII (rFVIIa, eptacog alfa activated) has greatly ad...
In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and...
Haemophilia A is a bleeding disorder caused by deficiency of coagulation factor VIII (FVIII) which l...
In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and...
From Springer Nature via Jisc Publications RouterHistory: received 2022-09-02, accepted 2023-02-27, ...
Introduction: Haemophilia A is a rare bleeding disorder caused by coagulation factor VIII (FVIII) de...
WOS: 000320552100029PubMed ID: 23557542The ONE Registry (OR) was an international prospective observ...
Introduction: This study compared the efficacy of Aryoseven with Novoseven to control bleeding episo...
Haemophilia therapy has undergone very rapid evolution in the last 10 years. The major limitation of...
Aims: Prophylaxis with standard-acting recombinant factor IX (rFIX) in hemophilia B patients require...
Heng Joo Ng, Lai Heng LeeDepartment of Haematology, Singapore General Hospital, SingaporeAbstract: I...
Self‐administration of factor and bypassing agents by persons with hemophilia in the home setting is...
On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and m...
The Hemostasis and Thrombosis Research Society Registry was used to monitor the postapproval use and...
The availability of recombinant activated factor VII (rFVIIa, eptacog alfa activated) has greatly ad...
The availability of recombinant activated factor VII (rFVIIa, eptacog alfa activated) has greatly ad...
In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and...
Haemophilia A is a bleeding disorder caused by deficiency of coagulation factor VIII (FVIII) which l...
In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and...
From Springer Nature via Jisc Publications RouterHistory: received 2022-09-02, accepted 2023-02-27, ...
Introduction: Haemophilia A is a rare bleeding disorder caused by coagulation factor VIII (FVIII) de...
WOS: 000320552100029PubMed ID: 23557542The ONE Registry (OR) was an international prospective observ...
Introduction: This study compared the efficacy of Aryoseven with Novoseven to control bleeding episo...
Haemophilia therapy has undergone very rapid evolution in the last 10 years. The major limitation of...
Aims: Prophylaxis with standard-acting recombinant factor IX (rFIX) in hemophilia B patients require...
DOI
Add to ORKG